Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation
J Styczynski - Infectious diseases and therapy, 2018 - Springer
Cytomegalovirus (CMV) is an agent of global infection, and its acquisition in a population is
characterized by an age-dependent rise in seropositivity. After primary infection, CMV …
characterized by an age-dependent rise in seropositivity. After primary infection, CMV …
Complications, diagnosis, management, and prevention of CMV infections: current and future
M Boeckh - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Although major progress has been made in the prevention of CMV disease after
hematopoietic cell transplantation (HCT), specific problems remain and available antiviral …
hematopoietic cell transplantation (HCT), specific problems remain and available antiviral …
Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation
S Ganepola, C Gentilini, U Hilbers, T Lange… - Bone marrow …, 2007 - nature.com
Human cytomegalovirus (CMV) is a major cause of death after transplantation. The
frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during …
frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during …
Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients
Background Although initial therapy for cytomegalovirus (CMV) is usually successful, a
significant subset of patients may have recurrent viremia. However, the epidemiology and …
significant subset of patients may have recurrent viremia. However, the epidemiology and …
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
M Boeckh, W Leisenring, SR Riddell… - Blood, The Journal …, 2003 - ashpublications.org
Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
[HTML][HTML] Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation
JF Camargo, KV Komanduri - Hematology/oncology and stem cell therapy, 2017 - Elsevier
Despite the refinements in molecular methods for the detection of cytomegalovirus (CMV)
and the advent of highly effective preemptive strategies, CMV remains a leading cause of …
and the advent of highly effective preemptive strategies, CMV remains a leading cause of …
Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis
P Ljungman, R Brand, H Einsele, F Frassoni… - Blood, 2003 - ashpublications.org
Cytomegalovirus (CMV) has been a major cause of morbidity and mortality after allogeneic
stem cell transplantation (SCT). The importance of the recipient's serologic status is …
stem cell transplantation (SCT). The importance of the recipient's serologic status is …
Clinical aspects of CMV infection after stem cell transplantation
H Hebart, H Einsele - Human immunology, 2004 - Elsevier
Cytomegalovirus (CMV) infection is one of the most important infectious complications after
stem cell transplantation (SCT). Major improvements in the management of CMV infection …
stem cell transplantation (SCT). Major improvements in the management of CMV infection …
The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation
P Ljungman - Current opinion in hematology, 2014 - journals.lww.com
The role of cytomegalovirus serostatus on outcome of hematop... : Current Opinion in
Hematology The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell …
Hematology The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell …
[HTML][HTML] Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and …
J Liu, J Kong, YJ Chang, H Chen, YH Chen… - Clinical Microbiology …, 2015 - Elsevier
Pre-emptive therapy is an effective approach for cytomegalovirus (CMV) control; however,
refractory CMV still occurs in a considerable group of recipients after allogeneic …
refractory CMV still occurs in a considerable group of recipients after allogeneic …